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Diﬀ erent liposomal 
amphotericin B 
formulations for 
visceral leishmaniasis
In response to the promising results 
of a single dose of liposomal ampho-
tericin B (AmBisome) to treat 
visceral leishmaniasis in Bangladesh, 
Nilima Kshirsagar (April issue),1 
suggests that an alternative form—
Fungisome—might soon qualify for 
similar use and application. 
AmBisome was the ﬁ rst formulation 
of amphotericin B that maximised 
eﬃ  cacy in visceral leishmaniasis while 
minimising toxic eﬀ ects. Fungisome 
is the brand name of a liposomal 
ampho tericin B product developed 
in Kshirsagar’s own laboratory2 and 
marketed by LifeCare Innovations. 
It cannot be considered a generic of 
AmBisome because the liposomal 
compositions are not comparable. To 
transform multi lamellar vesicles into 
small unilamellar vesicles, Fungisome 
requires sonica tion for 45 min before 
administration, which is technically 
very challenging in programmatic 
settings for visceral leishmaniasis. 
Moreover, published evidence on the 
efficacy and safety of Fungisome in 
visceral leishmaniasis, either in single-
dose or multidose regimens, is very 
limited.3 The phase 2–3 clinical trials that 
Kshirsagar mentions were actually in 
fungal infections.2 An ongoing phase 2 
trial is assessing single-dose Fungisome 
for visceral leishmaniasis in India.4
Beyond Fungisome, other products 
could be considered as generics 
of liposomal amphotericin B. Bio-
equivalence to AmBisome has to be 
established then through adapted 
processes.4 Before any generic product 
can be used for visceral leishmaniasis, 
liposomal ampho tericin B suppliers 
should submit their products to the 
WHO Prequalification Programme, 
the remit of which has been expanded 
to liposomal ampho tericin B,5 to 
determine which medicines are 
quality-assured and bioequivalent to 
AmBisome. This is the only safeguard 
to avoid exposing visceral leish-
maniasis patients to products with an 
unassessed safety and eﬃ  cacy proﬁ le.
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For the ongoing trial of single-
dose Fungisome for visceral 
leishmaniasis in India see 
http://www.ctri.nic.in/
Clinicaltrials/pmaindet2.
php?trialid=3687
